Shares of Roche Holding Ltd. (OTCMKTS:RHHBY) have earned a consensus recommendation of “Hold” from the fourteen ratings firms that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $38.00.

A number of research analysts have issued reports on the stock. Citigroup downgraded shares of Roche from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 18th. Berenberg Bank downgraded shares of Roche from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Cowen restated a “buy” rating and set a $38.00 target price on shares of Roche in a research report on Tuesday, September 19th. BNP Paribas cut Roche from a “neutral” rating to an “underperform” rating in a research note on Tuesday, September 26th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Roche in a research note on Thursday, December 7th.

Hedge funds have recently made changes to their positions in the company. Stonebridge Capital Advisors LLC bought a new stake in shares of Roche in the 3rd quarter valued at about $221,000. Patten Group Inc. increased its stake in Roche by 12.2% during the 3rd quarter. Patten Group Inc. now owns 29,741 shares of the company’s stock worth $847,000 after purchasing an additional 3,239 shares in the last quarter. Sterling Capital Management LLC increased its stake in Roche by 4.6% during the 3rd quarter. Sterling Capital Management LLC now owns 58,107 shares of the company’s stock worth $1,856,000 after purchasing an additional 2,535 shares in the last quarter. Lenox Wealth Management Inc. increased its stake in Roche by 49.0% during the 3rd quarter. Lenox Wealth Management Inc. now owns 98,282 shares of the company’s stock worth $3,145,000 after purchasing an additional 32,335 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its stake in Roche by 5.6% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 3,806,074 shares of the company’s stock worth $121,794,000 after purchasing an additional 200,394 shares in the last quarter. 0.58% of the stock is owned by institutional investors.

Roche (OTCMKTS RHHBY) traded down $0.16 during trading on Friday, reaching $30.81. 1,197,574 shares of the company’s stock were exchanged, compared to its average volume of 2,060,817. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.92 and a current ratio of 1.29. Roche has a 52 week low of $28.05 and a 52 week high of $36.82.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/20/brokerages-set-roche-holding-ltd-rhhby-pt-at-38-00.html.

Roche Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (OTCMKTS:RHHBY)

Receive News & Stock Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related stocks with our FREE daily email newsletter.